Circulating Nucleic Acid Based Biomarkers for Early Detection of Hepatocellular Carcinoma (HCC)

Overview

About this study

The goals of this study are to establish the role of circulating nucleic acid based biomarkers in early diagnosis, prognosis or treatment response in human diseases. These studies will determine whether alterations in circulating nucleic acids can distinguish between healthy and cancer tissue. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Diagnosis of cirrhosis
  • Age > 18 years of age
  • Able and willing to provide written informed consent

Exclusion Criteria:

  • Age < 18 years of age
  • Prior solid organ transplant

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Tushar Patel, M.B., Ch.B.

Closed for enrollment

Contact information:

Lori Chase B.S., CCRP

Chase.Lori@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20423516

Mayo Clinic Footer